The B Lymphocyte Antigen CD19 pipeline drugs market research report outlays comprehensive information on the B Lymphocyte Antigen CD19 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the B Lymphocyte Antigen CD19 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Musculoskeletal Disorders, and Hematological Disorders which include the indications B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Diffuse Large B-Cell Lymphoma, Systemic Lupus Erythematosus, Autoimmune Disorders, Idiopathic Inflammatory Myopathy (IIM), Dermatomyositis, Acquired (Autoimmune) Hemolytic Anemia, and Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). It also reviews key players involved in B Lymphocyte Antigen CD19 targeted therapeutics development with respective active and dormant or discontinued products.
The B Lymphocyte Antigen CD19 pipeline targets constitutes close to 471 molecules. Out of which, approximately 308 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 6, 6, 82, 77, 21, 7, 78, and 27 respectively. Similarly, the universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, and Discovery comprises 2, 63, 61, 8, 28, and 1 molecule.
B Lymphocyte Antigen CD19 overview
B Lymphocyte Antigen CD19, also known as CD19, is a cell surface protein that is primarily expressed on B cells, a type of white blood cell involved in the immune system. CD19 is a member of the immunoglobulin superfamily and plays a key role in B cell development and function. CD19 functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca (2+) stores. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen.
For a complete picture of B Lymphocyte Antigen CD19’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
